CDA | Evidence Driven
CDA | Evidence Driven

nivolumab ipilimumab

Details

Files
Generic Name:
nivolumab ipilimumab
Project Status:
Active
Therapeutic Area:
Melanoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0371-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Indicated in neoadjuvant setting for resectable stage III melanoma.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission receivedJuly 04, 2024
Review initiatedJuly 05, 2024
Expert committee meeting (initial)November 21, 2024

Files

Proposed Scope View PDF
Last Updated : October 30, 2024